EXTON, Pa., Nov. 10, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) announced today that it has completed its acquisition of all rights in the U.S. to manufacture, market and sell Vancocin Pulvules(R), the oral capsule formulation of Vancocin (vancomycin hydrochloride), as well as rights to certain related Vancocin products from Eli Lilly and Company (NYSE:LLY).
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. As a result of the acquisition completed today, ViroPharma will commercialize Vancocin Pulvules, approved for oral administration for treatment of enterocolitis caused by S. aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile. (For prescribing information, please download the package insert at http://www.viropharma.com/Vancocin_PI.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma and its development and commercial products, visit the company's website at www.viropharma.com.